One-Year Clinical Outcome of Inspiron Stent in All-Comers Population (Analysis from 790 Consecutive Patients).

AIMS: The goal of this study was to evaluate the performance of the InspironTM coronary stent (Scitech Medical™, Goiás, Brazil). The InspironTM sirolimus-eluting stent uses an ultrathin L-605 cobalt-chromium alloy with a 75 µm strut thickness platform coated with an abluminal biodegradable polymer. The polymer is eliminated from the body through the tricarboxylic acid cycle in 6-9 months, releasing 80% of the drug within 30 days after its deployment. METHODS: It was a prospective, single-center registry. To represent clinical practice, all patients undergoing percutaneous coronary intervention were included in this registry. There were no exclusion criteria. Clinical follow-ups were performed at twelve months. The endpoints were the occurrence of all-cause death, definite stent thrombosis, and new revascularization. RESULTS: Between November 2017 and May 2019, 790 patients were included (1067 lesions). The mean age was 60.42 ± 14.94 years, and 74.7% presented with acute coronary syndrome. Diabetes mellitus was present in 43.9% of patients, and previous myocardial infarction and previous percutaneous coronary intervention were present in 17.9% and 11.3%, respectively. Angiographic success was achieved in 99.1%. The incidence of all-cause death was 11.5% (6.2% in-hospital and 5.3% in the follow-up) and definitive stent thrombosis was 0.2%. New revascularization was performed in only 5.8% (target lesion revascularization: 2.2%; progression of disease in another lesion: 3.6%). Based on the multivariate regression analysis, only chronic renal failure was an independent predictor of adverse events (OR: 3.3; 95% CI: 1.22-8.92). CONCLUSION: The result of this single-center registry demonstrates the safety and excellent performance of the InspironTM stent in daily clinical practice with a low rate of adverse cardiac events.

Carbohydrate antigen 125 for mortality risk prediction following acute myocardial infarction.

Carbohydrate antigen 125 (CA125) is a congestion and inflammation biomarker and has been proved to be related to a worse prognosis in heart diseases. However, the precise relationship between elevated CA125 in patients with ST-segment elevation myocardial infarction (STEMI) has not yet been sufficiently studied. We set out to determine the association of CA125 with all-cause mortality at 6 months in STEMI. CA125, N-terminal pro brain natriuretic peptide (NTproBNP) and high sensitive C-reactive protein (hs-CRP) were measured in 245 patients admitted consecutively with STEMI undergoing coronary angioplasty. The mean age in our sample was 63.7 years, 64.9% were males, 28.3% had diabetes and 17.7% presented with acute heart failure (Killip ≥ 2). The median serum level of CA125 was 8.1 U/ml. At 6 months, the rate of all-cause mortality was 18% (44 patients). Receiver operating characteristic curve analysis demonstrated that CA125 presented similar performance to predict mortality as NTproBNP and hs-CRP. Patients with CA125 ≥ 11.48 had a higher rate of mortality (Hazard Ratio = 2.07, 95% confidence interval = 1.13-3.77, p = 0.017) than patients with CA125 < 11.48. This study suggests that elevated CA125 levels might be used to identify patients with STEMI with a higher risk of death at 6 months. CA125 seems to be a similar predictor of mortality compared to NTproBNP and hs-CRP.

Coronary Angioplasty with Stent in Woman with Active Vaginal Bleeding

Uterine leiomyoma and coronary artery disease are two common diseases in women. However, the association of uterine bleeding caused by leiomyoma with unstable coronary syndrome is not frequent. Here we describe a case of a patient with active vaginal bleeding and unstable angina who underwent a unique approach by performing percutaneous procedures. The report demonstrates that new interventional options can be used to control active bleeding in patients in need of coronary angioplasty

Predictors of coronary stent thrombosis: a case-control study.

To verify the frequency and predictors associated with stent thrombosis (ST) in a developing country. Observational, case-control study including 2535 consecutive patients undergoing percutaneous coronary intervention (PCI) in two reference hospitals in Brazil, from October 2013 to December 2015. ST patients were matched to controls in a 1:3 ratio for gender, age, procedure indication, and performing hospital. From the total sample, 65 (2.5%) ST occurred and were matched with 195 controls (age 64.9 ± 11.8 years; hypertension, 78.8%; diabetes, 30%). Clopidogrel and aspirin early withdrawal (OR 19.25; 95% CI 1.66-23.52; p < 0.01 and OR 4.36; 95% CI 1.81-10.50; p = 0.001, respectively), hypertension (OR 3.64; 95% CI 1.38-9.61; p = 0.006), dyslipidemia (OR 2.84; 95% CI 1.48-5.45; p = 0.002), smoking (OR 3.09; 95% CI 1.28-7.43; p = 0.02), body mass index ≥ 30 kg/m2 (OR 2.10; 95% CI 1.02-4.49; p = 0.012), previous myocardial infarction (OR 2.98; 95% CI 1.14-7.47; p < 0.001), bifurcation lesion (OR 2.44; 95% CI 1.05-5.67; p = 0.03), and ≥ 3 stents (OR 3.90; 95% CI 1.78-8.52; p = 0.002) were associated with ST. Stent type, diameter or length, severity of coronary artery disease, calcified lesions, and thrombus were not associated with ST. We found a similar frequency of ST from developed countries and identified strong predictors (clopidogrel and aspirin withdrawal, hypertension, dyslipidemia, smoking, obesity, previous myocardial infarction, bifurcation lesion, number of stents), which are in line with reports from developed countries.

Varizes de fundo gástrico na hipertensão portal esquistossomótica: resultados cirúrgicos / Gastric fundus varices in schistossomotic portal hypertension: surgical results

OBJETIVO: Apresentar dados epidemiológicos de pacientes esquistossomóticos na forma hepatoesplênica com varizes do fundo gástrico, assim como avaliar os resultados de uma estratégia cirúrgica no manuseio destas varizes. MÉTODO: No período de janeiro de 1992 à julho de 2001 foram acompanhados no Serviço de Cirurgia Geral do Hospital das Clínicas da Universidade Federal de Pernambuco 125 pacientes submetidos à esplenectomia com ligadura da veia gástrica esquerda (LVGE), desvascularização da grande curvatura do estômago e esclerose endoscópica pós-operatória, para o tratamento da hipertensão portal esquistossomótica com antecedentes de hemorragia digestiva. Quando da presença de varizes de fundo gástrico (44/125) foi associado ao procedimento cirúrgico, a abertura do estômago e sutura das varizes. RESULTADOS: Varizes de fundo gástrico foram identificadas em 35,2 por cento (44/125) dos pacientes com esquistossomose hepatoesplênica e antecedentes de hemorragia digestiva alta. Durante o seguimento de 26 meses o procedimento cirúrgico erradicou 76,5 por cento das varizes de fundo gástrico. A incidência de trombose da veia porta no período pós-operatório foi maior no grupo de pacientes sem varizes de fundo gástrico (16,3 por cento) quando comparado com os pacientes portadores de varizes de fundo gástrico (8,8 por cento), sem que, no entanto, esta diferença tivesse respaldo estatístico (p = 0,62). Não se identificou correlação entre a presença de varizes do fundo gástrico e o grau de fibrose periportal e o peso do baço. Na análise bioquímica e hematológica, no período pré-operatório dos grupos estudados, o número de leucócitos foi estatisticamente menor no grupo de pacientes que apresentavam varizes de fundo gástrico. CONCLUSÃO: A esplenectomia associada a desvascularização da grande curvatura do estômago, ligadura da veia gástrica esquerda, gastrotomia e sutura da varizes de fundo gástrico, erradicou 76,5 por cento das varizes de fundo gástrico...

BACKGROUND: The aim of this study is to present epidemiological data and evaluate a surgical approach in the treatment of gastric fundus varices in patients with hepatosplenic shistosomiasis. METHODS: During the period of January 1992 and July 2001, 125 patients underwent splenectomy, ligation of the left gastric vein (LLGV), devascularization of the great stomach curvature and post-operative endoscopic sclerotherapy for the treatment of hepatic-splenic schistosomiasis with previous gastrointestinal haemorrhages. In the patients who presented gastric varices in the pre-operative endoscopy (44/125), a gastrotomy and an obliterating running suture were also performed intraoperatively. RESULTS: Gastric fundus varices were observed in 35,2 percent of all patients with hepatic-splenic schistosomiasis with previous gastrointestinal haemorrhages (44/125). The surgical treatment proposed eradicated 76,5 percent of the gastric fundus varices in a mean follow-up period of 26 months. Portal vein thrombosis was higher in the group of patients without fundus grastric varices (16,3 percent) when compared with fundus gastric varices patients (8,8 percent). This difference was not statistically significant (p=0,62). There was no correlation between the presence of fundus gastric varices and the degree of periportal fibrosis or the weight of the spleen. Despite a statistically lower number of white blood cells in the gastric fundus varices, no other differences were identified in the preoperative haematological and biochemical data. CONCLUSIONS: The authors concluded that patients underwent splenectomy, ligation of the left gastric vein, devascularisation of the great stomach curvature, post-operative endoscopic sclerotherapy, gastrotomy and an obliterating running suture of the fundus gastric varices, eradicated 76,5 percent of the fundus gastric varices, in a follow-up of 26 months.

Peso do baço como fator prognóstico do tratamento cirúrgico de pacientes portadores de esquistossomose mansônica / Spleen weight as risk factor in the surgical treatment of patients with schistosoma mansoni

OBJETIVO: Analisar pré-operatoriamente o peso do baço como fator prognóstico do tratamento cirúrgico de pacientes portadores de esquistossomose mansônica. MÉTODOS: Foram analisados 114 pacientes, portadores de esquistossomose mansônica com antecedentes de hemorragia digestiva, submetidos a tratamento cirúrgico. Os pacientes foram divididos em três grupos: Grupo 1 - baço menor que 500 gramas (17); Grupo 2 - baço entre 500 e 1.000 gramas (58); Grupo 3 - baço acima de 1.000 gramas (39). RESULTADOS: No Grupo 1 a recidiva hemorrágica foi de 17,6 por cento, trombose da veia porta de 5,9 por cento e não houve mortalidade. A incidência de hiperesplenismo pré-operatório foi de 29,4 por cento e o calibre da veia porta foi de 1,1cm. No Grupo 2 a recidiva hemorrágica foi de 15,5 por cento, trombose da veia porta de 10,3 por cento e a mortalidade de quatro pacientes (6,9 por cento) (dois pacientes no período pós-operatório e dois no seguimento tardio, hepatocarcinoma e hemorragia digestiva). A incidência de hiperesplenismo foi de 53,4 por cento e o calibre médio da veia porta foi de 1,4cm. No Grupo 3 a recidiva hemorrágica foi de 12,8 por cento, trombose da veia porta de 5,1 por cento e uma mortalidade tardia de dois pacientes (linfoma e infarto agudo do miocárdio). A incidência de hiperesplenismo foi de 76,9 por cento e o calibre da veia porta foi de 1,5cm. CONCLUSÕES: O peso do baço apresenta relação com o hiperesplenismo pré-operatório, calibre da veia porta e permanência hospitalar pós-operatória. Não encontramos relação com a incidência de varizes de fundo gástrico, recidiva de sangramento digestivo, trombose da veia porta, grau de fibrose periportal e dados bioquímicos.

BACKGROUND: Searching for that risk factors that could commit surgical treatment of patient with schistosomiasis, the authors analyzed the spleen as a prognostic factor. METHODS: Between 1992 and 1998, 114 patients underwent splenectomy with ligation of the left gastric vein (LLGV) and devascularisation of the great stomach curvature, followed by post-operative endoscopic sclerotherapy for the treatment of hepatic-splenic schistosomiasis with previous gastrointestinal haemorrhages. A clinical/laboratorial analysis was performed. Patients were divided into 3 groups according to the weight of the spleen, in the moment of the accomplishment of the histologycal cuts: GROUP I - spleen smaller than 500 grams (17); GROUP II - spleen between 500 and 1000 grams (58) and; GROUP III - spleen greater than 1000 grams (39). RESULTS: Patients of GROUP I presented rebleeding rate of 17,6 percent, thrombosis of the portal vein of 5,9 percent and there was not mortality. The incidence of preoperative hipersplenism was 29,4 percent and the caliber of the portal vein was 1,1 cm. In GROUP II the rebleeding rate was of 15,5 percent, thrombosis of the portal vein of 10,3 percent and the mortality incidence of hiperplenism of 4 patient (6,9 percent), 2 patients in the immediate postoperative period and 2 in the late followup (hepatocarcinoma and digestive hemorrhage). The hipersplenism incidence was of 53,4 percent and preoperative mean caliber of the portal vein was 1,4cm. In GROUP III the rebleeding incidence was 12,8 percent, thrombosis of the portal vein 5,1 percent and a late mortality of 2 patient (linfoma and miocardium infarct). The hipersplenism incidence was of 76,9 percent and the caliber of the portal vein was of 1,5 cm. CONCLUSIONS: Weight of the spleen presents relationship with preoperative hipersplenism, with portal vein caliber and postoperative hospitalar stay. There was no relationship with fundus gastric varices, rebleeding rate, portal vein...